Gubra
  • Services
    • Liver
    • Kidney
    • Heart
    • Obesity
    • Diabetes
    • 3D Imaging
    • Customized services
    • CRO Lung
  • Discovery
    • Target Discovery
    • Drug Discovery
    • StreaMLine
  • Capabilities
    • In vivo pharmacology
    • Histology & Stereology
    • Imaging
    • NGS & Bioinformatics
    • Ex vivo assays
    • Drug Profiling
    • Peptide Chemistry
    • Gubra video gallery
  • Publications
  • Careers
  • About us
    • Company
    • Leadership
    • Events
    • Webinars
    • News
    • CSR
Select Page

muusfoto_IMG08998

Recent Posts

  • Gubra ApS and Silence Therapeutics plc collaborate to develop RNAi therapies against novel liver-directed targets from Gubra’s streaMLine platform
  • Gubra launches NeuroPedia – a mouse brain atlas for virtual neuroscience
  • Gubra and Bayer AG collaborate to develop next generation cardiorenal treatments
  • Drug candidate from obesity collaboration between Gubra and Boehringer Ingelheim enters clinical phase 1 trial
  • Annual results 2020: A thriving core business and razor-sharp biotech profile

Recent Comments

    Archives

    • February 2022
    • January 2022
    • September 2021
    • August 2021
    • May 2021
    • March 2021
    • December 2020
    • June 2020
    • May 2020
    • March 2020
    • October 2019
    • June 2019
    • May 2019
    • June 2018
    • September 2017
    • August 2017
    • June 2016
    • September 2013

    Categories

    • News
    • Press Release
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • Company
    • Careers
    • CSR
    • Contact
    • Privacy policy
    © 2022 Gubra
    Manage Cookie Consent
    close
    We use cookies to optimize our website and our service.
    Functional
    Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage third parties Manage vendors Read more about these purposes
    Preferences
    {title} {title} {title}

      Gubra Services

      Liver (NASH)

      Benefit from our extensive know-how in NASH and test your compound in our validated DIO NASH mouse models.

      Learn more
      Kidney

      Check out our novel rodent models of diabetic nephropathy.

      Learn more
      3D Imaging

      Use quantitative light-sheet fluoresence microscopy to validate pre-clinical endpoints.

      Learn more
      Obesity

      Tap into our vast scientific experience with diet-induced obesity (DIO) models and other commercially available models.

      Learn more
      Heart (CVD)

      Check out our novel rodent models of cardiovascular disease.

      Learn more
      Brain

      Check out our capabilities in neurodegenerative diseases.

      Learn more
      Diabetes

      Qualify and advance your assessment of novel compounds to treat type 2 diabetes and diabetic complications.

      Learn more
      Lung (IPF)

      Check out our services within lung diseases.

      Learn more